(Q36296255)

13 August 2017

Metformin use and risk of prostate cancer: results from the REDUCE study (English)

1 reference

13 August 2017

1 reference

Daniel M Moreira

6

0 references

author name string

Tom Feng

1

1 reference

13 August 2017

Xizi Sun

2

1 reference

13 August 2017

Lauren E Howard

3

1 reference

13 August 2017

Adriana C Vidal

4

1 reference

13 August 2017

Alexis R Gaines

5

1 reference

13 August 2017

Ramiro Castro-Santamaria

7

1 reference

13 August 2017

Gerald L Andriole

8

1 reference

13 August 2017

Stephen J Freedland

9

1 reference

13 August 2017

9 September 2015

1 reference

Cancer Prevention Research

13 August 2017

1 reference

13 August 2017

8

1 reference

13 August 2017

11

1 reference

13 August 2017

1055-1060

1 reference

Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

30 September 2017

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Metformin inhibits melanoma development through autophagy and apoptosis mechanisms.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Effect of dutasteride on the risk of prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Metformin and reduced risk of cancer in diabetic patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Role of AMP-activated protein kinase in mechanism of metformin action

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Metformin use and prostate cancer risk

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Association between metformin use and risk of prostate cancer and its grade

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Association between metabolic syndrome, diabetes mellitus and prostate cancer risk

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Chemoprevention of prostate cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4651624

Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study

21 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26353947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Metformin and the incidence of prostate cancer in patients with type 2 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26353947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1940-6207.CAPR-15-0141

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

26353947

1 reference